Media coverage about BioTelemetry (NASDAQ:BEAT) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioTelemetry earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 45.8747512995534 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
A number of equities analysts have recently commented on BEAT shares. Zacks Investment Research cut shares of BioTelemetry from a “hold” rating to a “strong sell” rating in a report on Thursday, November 2nd. Dougherty & Co reaffirmed a “buy” rating and issued a $40.00 target price on shares of BioTelemetry in a report on Wednesday, November 8th. BidaskClub raised shares of BioTelemetry from a “sell” rating to a “hold” rating in a report on Wednesday, December 27th. Raymond James Financial started coverage on shares of BioTelemetry in a report on Thursday, October 26th. They issued an “outperform” rating and a $37.00 target price on the stock. Finally, SunTrust Banks started coverage on shares of BioTelemetry in a report on Monday, October 23rd. They issued a “buy” rating and a $41.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $42.86.
BioTelemetry (BEAT) traded up $0.60 during trading hours on Friday, reaching $31.65. 350,697 shares of the company were exchanged, compared to its average volume of 429,205. BioTelemetry has a 1 year low of $23.30 and a 1 year high of $39.20. The company has a current ratio of 1.60, a quick ratio of 1.48 and a debt-to-equity ratio of 0.75. The stock has a market cap of $1,010.00, a price-to-earnings ratio of 24.16, a price-to-earnings-growth ratio of 1.38 and a beta of 0.67.
BioTelemetry Company Profile
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.